Objective:Acitretin is a widely used systemic retinoid that is to treat psoriasis but has significant variations in efficacy and adverse events(AEs)among individuals.This study aimed to determine the impact of AEs ass...Objective:Acitretin is a widely used systemic retinoid that is to treat psoriasis but has significant variations in efficacy and adverse events(AEs)among individuals.This study aimed to determine the impact of AEs associated with acitretin treatment of moderate-to-severe plaque psoriasis on the Dermatology Life Quality Index(DLQI)and Hospital Anxiety and Depression Scale(HADS)scores.Methods:This prospective,observational,single-center study was conducted from March 2021 to June 2022 and analyzed 116 patients with moderate-to-severe plaque psoriasis treated with acitretin who were followed up for 12 weeks.The primary outcome was the incidence of AEs related to acitretin,and the secondary objective was to investigate the effect of AEs on the DLQI and HADS scores.The generalized linear models were used to assess the association between AEs related to acitretin and DLQI scores or HADS scores,and the association between the involved system/tissue and DLQI scores or HADS scores.Results:A final total of 45 patients were included in the analysis,and a total of 157 treatment-related AEs involving nine organs or systems were reported in 41 patients.The most common AE was skin-or mucosa-related,with 72 cumulative events in 31 patients.AEs also commonly affected the endocrine,digestive,and genitourinary systems.Compared with the group with 0-2 AEs,the group with 3-5 AEs had a significantly increased DLQI score by 5.49 points(95%CI,1.47-9.51)(P=0.0089).Compared with AEs involving 0 to 1 system,AEs affecting 2 to 3 systems resulted in a significant increase in the DLQI score by 5.75 points(95%CI,1.67-9.83)(P=0.0071).Generalized linear models showed no statistically significant associations between AEs and the HADS scores.Conclusion:Our study demonstrates a high incidence of acitretin-related AEs.These AEs may affect quality of life but rarely cause psychological problems such as anxiety and depression.展开更多
Introduction Subacute cutaneous lupus erythematosus (SCLE),discoid lupus erythematosus (DLE),and systemic lupus erythematosus (SLE) are three of the distinctive subsets of lupus erythematosus (LE).Peter Schur,in 1971,...Introduction Subacute cutaneous lupus erythematosus (SCLE),discoid lupus erythematosus (DLE),and systemic lupus erythematosus (SLE) are three of the distinctive subsets of lupus erythematosus (LE).Peter Schur,in 1971,coined the term 'rhupus' to describe the patients satisfying the criteria of both SLE and rheumatoid arthritis (RA)[1].In 2013,the globally cumulative number of rhupus cases reported was about 140[2].RA combined with SCLE has also been reported,while the RA with DLE has never been described.Herein,we report a case of RA,who developed DLE after 10 years of RA.展开更多
基金sponsored by the National Natural Science Foundation of China(Nos.81872522,82073429,82203913)Youth Program of National Natural Science Foundation of China(No.82003335)+5 种基金Innovation Program of Shanghai Municipal Education Commission(No.2019-01-07-00-07-E00046)Clinical Research Plan of SHDC(Nos.SHDC2020CR1014B and SHDC2020CR6022),Program of Shanghai Academic Research Leaders(No.20XD1403300)Program of Science and Technology Commission of Shanghai Municipality(No.18140901800)Excellent Subject Leader Program of Shanghai Municipal Commission of Health and Family Planning(No.2018BR30)Clinical Training Program(No.lcfy2020-02)Fundamental Research Funds for the Central Universities(22120220602).
文摘Objective:Acitretin is a widely used systemic retinoid that is to treat psoriasis but has significant variations in efficacy and adverse events(AEs)among individuals.This study aimed to determine the impact of AEs associated with acitretin treatment of moderate-to-severe plaque psoriasis on the Dermatology Life Quality Index(DLQI)and Hospital Anxiety and Depression Scale(HADS)scores.Methods:This prospective,observational,single-center study was conducted from March 2021 to June 2022 and analyzed 116 patients with moderate-to-severe plaque psoriasis treated with acitretin who were followed up for 12 weeks.The primary outcome was the incidence of AEs related to acitretin,and the secondary objective was to investigate the effect of AEs on the DLQI and HADS scores.The generalized linear models were used to assess the association between AEs related to acitretin and DLQI scores or HADS scores,and the association between the involved system/tissue and DLQI scores or HADS scores.Results:A final total of 45 patients were included in the analysis,and a total of 157 treatment-related AEs involving nine organs or systems were reported in 41 patients.The most common AE was skin-or mucosa-related,with 72 cumulative events in 31 patients.AEs also commonly affected the endocrine,digestive,and genitourinary systems.Compared with the group with 0-2 AEs,the group with 3-5 AEs had a significantly increased DLQI score by 5.49 points(95%CI,1.47-9.51)(P=0.0089).Compared with AEs involving 0 to 1 system,AEs affecting 2 to 3 systems resulted in a significant increase in the DLQI score by 5.75 points(95%CI,1.67-9.83)(P=0.0071).Generalized linear models showed no statistically significant associations between AEs and the HADS scores.Conclusion:Our study demonstrates a high incidence of acitretin-related AEs.These AEs may affect quality of life but rarely cause psychological problems such as anxiety and depression.
文摘Introduction Subacute cutaneous lupus erythematosus (SCLE),discoid lupus erythematosus (DLE),and systemic lupus erythematosus (SLE) are three of the distinctive subsets of lupus erythematosus (LE).Peter Schur,in 1971,coined the term 'rhupus' to describe the patients satisfying the criteria of both SLE and rheumatoid arthritis (RA)[1].In 2013,the globally cumulative number of rhupus cases reported was about 140[2].RA combined with SCLE has also been reported,while the RA with DLE has never been described.Herein,we report a case of RA,who developed DLE after 10 years of RA.